Your selections:
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?
- Giovannoni, Gavin, Hawkes, Christopher H., Lechner-Scott, Jeannette, Levy, Michael, Yeh, E. Ann
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis
- Spelman, T., Mekhael, L., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand'Maison, F.
Are you sure you would like to clear your session, including search history and login status?